Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: XYZAL

« Back to Dashboard
Xyzal is a drug marketed by Ucb Inc and is included in two NDAs. It is available from six suppliers.

The generic ingredient in XYZAL is levocetirizine dihydrochloride. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.

Summary for Tradename: XYZAL

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list12

Pharmacology for Tradename: XYZAL

Clinical Trials for: XYZAL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
XYZAL
levocetirizine dihydrochloride
SOLUTION;ORAL022157-001Jan 28, 2008RXYes<disabled><disabled>
Ucb Inc
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XYZAL

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
XYZAL
levocetirizine dihydrochloride
SOLUTION;ORAL022157-001Jan 28, 20085,698,558*PED<disabled>
Ucb Inc
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 20074,525,358<disabled>
Ucb Inc
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 20075,698,558*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: XYZAL

Drugname Dosage Strength RLD Submissiondate
levocetirizine dihydrochlorideOral Solution0.5 mg/mLXyzal1/14/2009
levocetirizine dihydrochlorideTablets5 mgXyzal12/17/2007
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc